Q2 2024 EPS Estimates for Eyenovia, Inc. (NASDAQ:EYEN) Increased by Analyst

Eyenovia, Inc. (NASDAQ:EYEN) – Equities research analysts at Brookline Capital Management raised their Q2 2024 EPS estimates for shares of Eyenovia in a report released on Thursday, May 16th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.18). The consensus estimate for Eyenovia’s current full-year earnings is ($0.59) per share. Brookline Capital Management also issued estimates for Eyenovia’s Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.54) EPS and FY2027 earnings at ($0.06) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a report on Thursday, May 16th.

Eyenovia Stock Performance

NASDAQ EYEN opened at $0.74 on Monday. The company has a market capitalization of $39.71 million, a P/E ratio of -0.98 and a beta of 1.71. The firm has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $1.40. Eyenovia has a 12-month low of $0.50 and a 12-month high of $3.31. The company has a quick ratio of 0.66, a current ratio of 0.88 and a debt-to-equity ratio of 3.72.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). During the same period in the prior year, the firm posted ($0.17) earnings per share.

Insider Buying and Selling at Eyenovia

In related news, major shareholder Stuart M. Grant acquired 100,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were purchased at an average price of $0.98 per share, for a total transaction of $98,000.00. Following the completion of the acquisition, the insider now owns 5,430,715 shares of the company’s stock, valued at $5,322,100.70. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In related news, major shareholder Stuart M. Grant acquired 100,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was purchased at an average cost of $0.98 per share, with a total value of $98,000.00. Following the acquisition, the insider now owns 5,430,715 shares of the company’s stock, valued at approximately $5,322,100.70. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Stuart M. Grant purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were purchased at an average price of $1.23 per share, for a total transaction of $61,500.00. Following the completion of the acquisition, the insider now owns 5,330,715 shares of the company’s stock, valued at approximately $6,556,779.45. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 160,717 shares of company stock valued at $176,433. 7.10% of the stock is currently owned by company insiders.

Institutional Trading of Eyenovia

Several hedge funds and other institutional investors have recently modified their holdings of EYEN. Armistice Capital LLC grew its position in shares of Eyenovia by 41.8% during the 4th quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock valued at $9,106,000 after purchasing an additional 1,290,979 shares in the last quarter. Vanguard Group Inc. lifted its position in Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the last quarter. PFG Investments LLC bought a new position in shares of Eyenovia during the 1st quarter valued at $69,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in Eyenovia in the fourth quarter worth about $84,000. Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.